Rizmoic Unia Europejska - słowacki - EMA (European Medicines Agency)

rizmoic

shionogi b.v. - naldemedine tosilate - zápcha - lieky na zápchu, periférne antagonisty opiátových receptorov - rizmoic je indikovaný na liečbu závislosti od opiátov-indukovanej zápcha (oic) u dospelých pacientov, ktorí v minulosti boli liečení s preháňadlo.

Iressa Unia Europejska - słowacki - EMA (European Medicines Agency)

iressa

astrazeneca ab - gefitinib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - iressa je indikovaný na liečbu dospelých pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer s aktiváciou mutácie pokožky-rastový faktor-receptor tyrozín kinase.

Sutent Unia Europejska - słowacki - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastické činidlá - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.